Log in

OTCMKTS:BNKLBionik Laboratories Stock Price, Forecast & News

+0.50 (+14.29 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $4.00
50-Day Range
MA: $1.85
52-Week Range
Now: $4.00
Volume957 shs
Average Volume1,571 shs
Market Capitalization$19.96 million
P/E RatioN/A
Dividend YieldN/A
Bionik Laboratories Corp., a robotics company, focuses on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The company specializes in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Systems, which include the InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND, an add-on module to be used with the InMotion ARM; and InMotion WRIST, a rehabilitation device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions. The company is also developing InMotion HOME, an upper extremity product that allows patients to extend their therapy for as long as needed while rehabilitating at home; and ARKE, a robotic lower body exoskeleton designed for wheelchair bound individuals suffering from spinal cord injuries, stroke, and other mobility disabilities. Bionik Laboratories Corp. was founded in 2010 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.83 out of 5 stars

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolOTCMKTS:BNKL



Sales & Book Value

Annual Sales$3.25 million
Book Value$11.71 per share


Net Income$-10,560,000.00
Net Margins-476.69%


Market Cap$19.96 million
Next Earnings Date7/7/2020 (Estimated)
OptionableNot Optionable

Receive BNKL News and Ratings via Email

Sign-up to receive the latest news and ratings for BNKL and its competitors with MarketBeat's FREE daily newsletter.

Bionik Laboratories (OTCMKTS:BNKL) Frequently Asked Questions

How has Bionik Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Bionik Laboratories' stock was trading at $1.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BNKL stock has increased by 128.6% and is now trading at $4.00. View which stocks have been most impacted by Coronavirus.

When is Bionik Laboratories' next earnings date?

Bionik Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, July 7th 2020. View our earnings forecast for Bionik Laboratories.

Has Bionik Laboratories been receiving favorable news coverage?

Media headlines about BNKL stock have been trending negative on Saturday, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Bionik Laboratories earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutBionik Laboratories.

Who are some of Bionik Laboratories' key competitors?

What other stocks do shareholders of Bionik Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionik Laboratories investors own include Co-Diagnostics (CODX), Ibio (IBIO), PerkinElmer (PKI), Pharmacyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Ascent Solar Technologies (ASTI), BioRestorative Therapies (BRTX) and Digital Ally (DGLY).

Who are Bionik Laboratories' key executives?

Bionik Laboratories' management team includes the following people:
  • Dr. Eric Michel Dusseux M.D., MSc, MBA, CEO & Director (Age 51)
  • Mr. Michal Prywata, Co-Founder, CTO & Director (Age 28)
  • Ms. Leslie N. Markow, Chief Financial Officer (Age 59)
  • Mr. William Harris, Marketing Director
  • Mr. Renaud Bertrand Maloberti, Chief Commercial Officer (Age 50)

What is Bionik Laboratories' stock symbol?

Bionik Laboratories trades on the OTCMKTS under the ticker symbol "BNKL."

How do I buy shares of Bionik Laboratories?

Shares of BNKL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bionik Laboratories' stock price today?

One share of BNKL stock can currently be purchased for approximately $4.00.

How big of a company is Bionik Laboratories?

Bionik Laboratories has a market capitalization of $19.96 million and generates $3.25 million in revenue each year. Bionik Laboratories employs 27 workers across the globe.

What is Bionik Laboratories' official website?

The official website for Bionik Laboratories is www.bioniklabs.com.

How can I contact Bionik Laboratories?

Bionik Laboratories' mailing address is 483 BAY STREET N105, TORONTO A6, M5G2C9. The company can be reached via phone at 416-640-7887 or via email at www.bioniklabs.com.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.